18F-FDG PET/CT for detection and localization of residual or recurrent disease in patients with multiple myeloma after stem cell transplantation

Standard

18F-FDG PET/CT for detection and localization of residual or recurrent disease in patients with multiple myeloma after stem cell transplantation. / Derlin, Thorsten; Weber, Christoph; Habermann, Christian R; Herrmann, Jochen; Wisotzki, Christian; Ayuk, Francis; Wolschke, Christine; Klutmann, Susanne; Kröger, Nicolaus.

In: EUR J NUCL MED MOL I, Vol. 39, No. 3, 01.03.2012, p. 493-500.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

APA

Vancouver

Bibtex

@article{da7596478d7148da9c2dc44411f980a8,
title = "18F-FDG PET/CT for detection and localization of residual or recurrent disease in patients with multiple myeloma after stem cell transplantation",
abstract = "PURPOSE: The aim of the study was to determine the diagnostic performance of (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT for the detection and localization of residual or recurrent disease in patients with multiple myeloma (MM) after stem cell transplantation.METHODS: A total of 197 whole-body (18)F-FDG PET/CT scans were performed in 99 patients with MM at different time points in the course of disease after autologous or allogeneic stem cell transplantation. Post-transplant PET/CT scans and clinical remission status as determined by the clinical gold standard (Uniform Response Criteria) were analysed and compared.RESULTS: A total of 576 focal osseous and extramedullary lesions were detected in 79 scans. Additional diffuse bone marrow involvement was detected in 17 patients. (18)F-FDG PET/CT had a sensitivity of 54.6%, a specificity of 82.1%, a positive predictive value of 82.3%, a negative predictive value of 54.2% and an overall accuracy of 65.5%. The sensitivity of (18)F-FDG PET/CT was shown to depend on the disease category according to the Uniform Response Criteria for myeloma.CONCLUSION: In patients with MM in the post-transplant setting, (18)F-FDG PET/CT may (1) contribute to the detection and localization of disease, (2) provide information about the extent of distinct myeloma manifestations and the total disease burden and (3) add information about the metabolic activity of disease, but (4) has substantially lower sensitivity for this purpose compared to the pretreatment setting.",
keywords = "Adult, Aged, Female, Fluorodeoxyglucose F18, Humans, Male, Middle Aged, Multimodal Imaging, Multiple Myeloma, Neoplasm, Residual, Positron-Emission Tomography, Recurrence, Reference Standards, Reproducibility of Results, Retrospective Studies, Stem Cell Transplantation, Tomography, X-Ray Computed, Transplantation, Autologous, Transplantation, Homologous",
author = "Thorsten Derlin and Christoph Weber and Habermann, {Christian R} and Jochen Herrmann and Christian Wisotzki and Francis Ayuk and Christine Wolschke and Susanne Klutmann and Nicolaus Kr{\"o}ger",
year = "2012",
month = mar,
day = "1",
doi = "10.1007/s00259-011-1993-8",
language = "English",
volume = "39",
pages = "493--500",
journal = "EUR J NUCL MED MOL I",
issn = "1619-7070",
publisher = "Springer",
number = "3",

}

RIS

TY - JOUR

T1 - 18F-FDG PET/CT for detection and localization of residual or recurrent disease in patients with multiple myeloma after stem cell transplantation

AU - Derlin, Thorsten

AU - Weber, Christoph

AU - Habermann, Christian R

AU - Herrmann, Jochen

AU - Wisotzki, Christian

AU - Ayuk, Francis

AU - Wolschke, Christine

AU - Klutmann, Susanne

AU - Kröger, Nicolaus

PY - 2012/3/1

Y1 - 2012/3/1

N2 - PURPOSE: The aim of the study was to determine the diagnostic performance of (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT for the detection and localization of residual or recurrent disease in patients with multiple myeloma (MM) after stem cell transplantation.METHODS: A total of 197 whole-body (18)F-FDG PET/CT scans were performed in 99 patients with MM at different time points in the course of disease after autologous or allogeneic stem cell transplantation. Post-transplant PET/CT scans and clinical remission status as determined by the clinical gold standard (Uniform Response Criteria) were analysed and compared.RESULTS: A total of 576 focal osseous and extramedullary lesions were detected in 79 scans. Additional diffuse bone marrow involvement was detected in 17 patients. (18)F-FDG PET/CT had a sensitivity of 54.6%, a specificity of 82.1%, a positive predictive value of 82.3%, a negative predictive value of 54.2% and an overall accuracy of 65.5%. The sensitivity of (18)F-FDG PET/CT was shown to depend on the disease category according to the Uniform Response Criteria for myeloma.CONCLUSION: In patients with MM in the post-transplant setting, (18)F-FDG PET/CT may (1) contribute to the detection and localization of disease, (2) provide information about the extent of distinct myeloma manifestations and the total disease burden and (3) add information about the metabolic activity of disease, but (4) has substantially lower sensitivity for this purpose compared to the pretreatment setting.

AB - PURPOSE: The aim of the study was to determine the diagnostic performance of (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT for the detection and localization of residual or recurrent disease in patients with multiple myeloma (MM) after stem cell transplantation.METHODS: A total of 197 whole-body (18)F-FDG PET/CT scans were performed in 99 patients with MM at different time points in the course of disease after autologous or allogeneic stem cell transplantation. Post-transplant PET/CT scans and clinical remission status as determined by the clinical gold standard (Uniform Response Criteria) were analysed and compared.RESULTS: A total of 576 focal osseous and extramedullary lesions were detected in 79 scans. Additional diffuse bone marrow involvement was detected in 17 patients. (18)F-FDG PET/CT had a sensitivity of 54.6%, a specificity of 82.1%, a positive predictive value of 82.3%, a negative predictive value of 54.2% and an overall accuracy of 65.5%. The sensitivity of (18)F-FDG PET/CT was shown to depend on the disease category according to the Uniform Response Criteria for myeloma.CONCLUSION: In patients with MM in the post-transplant setting, (18)F-FDG PET/CT may (1) contribute to the detection and localization of disease, (2) provide information about the extent of distinct myeloma manifestations and the total disease burden and (3) add information about the metabolic activity of disease, but (4) has substantially lower sensitivity for this purpose compared to the pretreatment setting.

KW - Adult

KW - Aged

KW - Female

KW - Fluorodeoxyglucose F18

KW - Humans

KW - Male

KW - Middle Aged

KW - Multimodal Imaging

KW - Multiple Myeloma

KW - Neoplasm, Residual

KW - Positron-Emission Tomography

KW - Recurrence

KW - Reference Standards

KW - Reproducibility of Results

KW - Retrospective Studies

KW - Stem Cell Transplantation

KW - Tomography, X-Ray Computed

KW - Transplantation, Autologous

KW - Transplantation, Homologous

U2 - 10.1007/s00259-011-1993-8

DO - 10.1007/s00259-011-1993-8

M3 - SCORING: Journal article

C2 - 22113619

VL - 39

SP - 493

EP - 500

JO - EUR J NUCL MED MOL I

JF - EUR J NUCL MED MOL I

SN - 1619-7070

IS - 3

ER -